SG11201605698XA - Enolase 1 (eno1) compositions and uses thereof - Google Patents
Enolase 1 (eno1) compositions and uses thereofInfo
- Publication number
- SG11201605698XA SG11201605698XA SG11201605698XA SG11201605698XA SG11201605698XA SG 11201605698X A SG11201605698X A SG 11201605698XA SG 11201605698X A SG11201605698X A SG 11201605698XA SG 11201605698X A SG11201605698X A SG 11201605698XA SG 11201605698X A SG11201605698X A SG 11201605698XA
- Authority
- SG
- Singapore
- Prior art keywords
- eno1
- enolase
- compositions
- Prior art date
Links
- 101710165425 Alpha-enolase Proteins 0.000 title 1
- 102100038910 Alpha-enolase Human genes 0.000 title 1
- 101150015836 ENO1 gene Proteins 0.000 title 1
- 101710184673 Enolase 1 Proteins 0.000 title 1
- 101100172356 Schizosaccharomyces pombe (strain 972 / ATCC 24843) eno101 gene Proteins 0.000 title 1
- 101100172357 Schizosaccharomyces pombe (strain 972 / ATCC 24843) eno102 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926913P | 2014-01-13 | 2014-01-13 | |
| US201462009783P | 2014-06-09 | 2014-06-09 | |
| US201562100881P | 2015-01-07 | 2015-01-07 | |
| PCT/US2015/011275 WO2015106295A2 (en) | 2014-01-13 | 2015-01-13 | Enolase 1 (eno1) compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605698XA true SG11201605698XA (en) | 2016-08-30 |
Family
ID=53524434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605698XA SG11201605698XA (en) | 2014-01-13 | 2015-01-13 | Enolase 1 (eno1) compositions and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10188708B2 (enExample) |
| EP (2) | EP3094341B1 (enExample) |
| JP (2) | JP6629234B2 (enExample) |
| KR (1) | KR20160106175A (enExample) |
| CN (3) | CN106659766B (enExample) |
| AU (2) | AU2015204452A1 (enExample) |
| BR (1) | BR112016016153A2 (enExample) |
| CA (2) | CA2936694A1 (enExample) |
| EA (1) | EA201691420A1 (enExample) |
| HK (1) | HK1231425A1 (enExample) |
| IL (1) | IL246720A0 (enExample) |
| MX (1) | MX2016009102A (enExample) |
| SG (1) | SG11201605698XA (enExample) |
| WO (2) | WO2015106295A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1231425A1 (zh) | 2014-01-13 | 2017-12-22 | Berg Llc | 烯醇酶1(eno1)組合物及其用途 |
| CN107847560A (zh) * | 2015-06-22 | 2018-03-27 | 博格有限责任公司 | 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途 |
| WO2017062363A1 (en) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| JP7042755B2 (ja) | 2016-06-05 | 2022-03-28 | バーグ エルエルシー | 患者層別化及び潜在的バイオマーカー同定のためのシステム及び方法 |
| CN107991493B (zh) * | 2017-11-22 | 2020-03-31 | 中国医科大学附属第一医院 | 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用 |
| CN112111462B (zh) * | 2020-09-14 | 2022-08-23 | 兰州大学 | 烯醇化酶eno1单克隆抗体及其应用 |
| KR20240099206A (ko) * | 2021-11-26 | 2024-06-28 | 후닐라이프 바이오테크놀로지, 인코포레이트 | 인간 질병을 치료하기 위해 세포외 알파-에놀라제를 표적화하여 해당과정을 조절하는 방법 |
| CN114533902A (zh) * | 2022-02-28 | 2022-05-27 | 河南师范大学 | 一种过表达lrrc15基因的质粒载体及其制备方法和应用 |
| CN115786317A (zh) * | 2022-12-12 | 2023-03-14 | 江苏三联生物工程股份有限公司 | 重组神经元特异性烯醇化酶及其制备方法与应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1350523B1 (en) | 1992-09-25 | 2007-05-16 | Boston Scientific Limited | Therapeutic conjugates inhibiting vascular smooth muscle cells |
| WO1996012737A2 (en) | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US20030044795A1 (en) | 1996-09-06 | 2003-03-06 | Inger Byrajalsen | Biochemical markers of the human endometrium |
| US7078375B1 (en) * | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
| US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| JP2003510033A (ja) | 1999-09-01 | 2003-03-18 | サブサイダリー ナンバースリー インコーポレイテッド | ヒト細胞遺伝子をダウンレギュレートすることにより、ヒト免疫不全ウイルス感染を阻止するための組成物および方法 |
| WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| EP1226280A4 (en) | 1999-10-25 | 2003-10-15 | Univ Princeton | GENETIC SEQUENCES ASSOCIATED WITH THE PROLIFERATION AND PATHOLOGIES OF NEURONAL CELLS |
| WO2001057069A2 (en) | 2000-02-02 | 2001-08-09 | Transgene S.A. | Targeting peptides |
| US20030203372A1 (en) | 2000-12-08 | 2003-10-30 | Ward Neil Raymond | Analysis method |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| US20040058326A1 (en) | 2001-07-27 | 2004-03-25 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
| US20050191627A1 (en) | 2001-09-28 | 2005-09-01 | Incyte Corporation | Enzymes |
| WO2003064501A1 (en) | 2002-01-31 | 2003-08-07 | Clarke Slemon | Conformationally restricted compounds as dendrimer cores |
| US20050222023A1 (en) | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
| JP2004081111A (ja) * | 2002-08-27 | 2004-03-18 | Yamaguchi Technology Licensing Organization Ltd | 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法 |
| EP2364716A3 (en) | 2002-11-08 | 2012-01-11 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| CN100446772C (zh) * | 2002-12-06 | 2008-12-31 | 法布罗根股份有限公司 | 一种稳定HIFα的制剂在制备治疗糖尿病的药物中的应用 |
| WO2004055519A2 (en) | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| WO2004061088A2 (en) | 2002-12-30 | 2004-07-22 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2004084950A2 (en) | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
| US7473531B1 (en) | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005073621A (ja) | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
| CA2540529C (en) | 2003-10-03 | 2012-03-13 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| JP2006528361A (ja) | 2004-07-06 | 2006-12-14 | クンイル ファーマシューティカル カンパニー リミテッド | アルドラーゼを含む網膜血管疾患診断用組成物およびその診断方法 |
| WO2007046818A2 (en) | 2004-11-16 | 2007-04-26 | Board Of Regents, The University Of Texas System | Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display |
| EP1843781B1 (en) | 2005-01-03 | 2015-03-18 | Jeon, Sook-yeong | Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| US20070248628A1 (en) | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| TWI304443B (en) | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| EP2121747A2 (en) | 2006-07-27 | 2009-11-25 | Oxford Genome Sciences (UK) Limited | New protein isoforms and uses thereof |
| ATE542831T1 (de) | 2006-09-29 | 2012-02-15 | Ribovax Biotechnologies Sa | Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind |
| US20100047256A1 (en) | 2007-01-25 | 2010-02-25 | Imperial Innovations Limited | Methods |
| WO2008134761A2 (en) | 2007-04-30 | 2008-11-06 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| AU2008273096B2 (en) | 2007-07-12 | 2013-05-02 | Academisch Ziekenhuis Leiden | Molecules for targeting compounds to various selected organs or tissues |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| JP5429707B2 (ja) | 2008-03-27 | 2014-02-26 | 国立大学法人群馬大学 | 微粒子およびその製造方法 |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| CN106173266A (zh) | 2008-07-18 | 2016-12-07 | 希尔氏宠物营养品公司 | 治疗与体重过重动物相关的疾病的组合物和方法 |
| EP2194382A1 (en) | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| IT1398782B1 (it) | 2009-09-11 | 2013-03-18 | Novelli | Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi. |
| US20120309684A1 (en) | 2009-11-30 | 2012-12-06 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011072290A2 (en) | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| AU2011257192A1 (en) | 2010-05-28 | 2013-01-10 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| EP2638058B1 (en) | 2010-11-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| ES2560012T3 (es) | 2011-05-10 | 2016-02-17 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias |
| GB201113814D0 (en) | 2011-08-10 | 2011-09-28 | Proteome Sciences R & D Gmbh & Co Kg | Materials and methods for determining sensitivity potential of compounds |
| IN2014MN00357A (enExample) | 2011-08-30 | 2015-06-19 | Medical Res Council | |
| CN109276717B (zh) | 2011-12-14 | 2022-04-12 | 得克萨斯系统大学董事会 | 用于癌症疗法的连带基因失活生物标志和靶标 |
| WO2014018851A1 (en) | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| EP2914247A4 (en) | 2012-10-30 | 2016-06-29 | Particle Sciences Inc | DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING ELEMENTS |
| HK1231425A1 (zh) | 2014-01-13 | 2017-12-22 | Berg Llc | 烯醇酶1(eno1)組合物及其用途 |
| CN107847560A (zh) | 2015-06-22 | 2018-03-27 | 博格有限责任公司 | 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途 |
| CA2992611A1 (en) | 2015-07-16 | 2017-01-19 | Berg Llc | Enolase 1 (eno1) compositions and uses thereof |
-
2015
- 2015-01-13 HK HK17105147.2A patent/HK1231425A1/zh unknown
- 2015-01-13 MX MX2016009102A patent/MX2016009102A/es unknown
- 2015-01-13 SG SG11201605698XA patent/SG11201605698XA/en unknown
- 2015-01-13 CA CA2936694A patent/CA2936694A1/en not_active Abandoned
- 2015-01-13 CN CN201580012892.XA patent/CN106659766B/zh active Active
- 2015-01-13 EP EP15735001.8A patent/EP3094341B1/en active Active
- 2015-01-13 AU AU2015204452A patent/AU2015204452A1/en not_active Abandoned
- 2015-01-13 EP EP15735142.0A patent/EP3094379A4/en not_active Withdrawn
- 2015-01-13 CN CN202011098097.6A patent/CN112336851A/zh active Pending
- 2015-01-13 CN CN201580012874.1A patent/CN106102835B/zh not_active Expired - Fee Related
- 2015-01-13 BR BR112016016153A patent/BR112016016153A2/pt not_active Application Discontinuation
- 2015-01-13 JP JP2016563909A patent/JP6629234B2/ja not_active Expired - Fee Related
- 2015-01-13 AU AU2015204451A patent/AU2015204451A1/en not_active Abandoned
- 2015-01-13 JP JP2016563908A patent/JP6644006B2/ja not_active Expired - Fee Related
- 2015-01-13 EA EA201691420A patent/EA201691420A1/ru unknown
- 2015-01-13 WO PCT/US2015/011275 patent/WO2015106295A2/en not_active Ceased
- 2015-01-13 US US14/596,208 patent/US10188708B2/en active Active
- 2015-01-13 KR KR1020167022300A patent/KR20160106175A/ko not_active Withdrawn
- 2015-01-13 WO PCT/US2015/011276 patent/WO2015106296A1/en not_active Ceased
- 2015-01-13 US US14/596,207 patent/US10188707B2/en active Active
- 2015-01-13 CA CA2936691A patent/CA2936691A1/en not_active Abandoned
-
2016
- 2016-07-11 IL IL246720A patent/IL246720A0/en unknown
-
2018
- 2018-11-28 US US16/203,016 patent/US20190307864A1/en not_active Abandoned
- 2018-11-28 US US16/202,989 patent/US11224641B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265844A (en) | Anti-lag-3 antibodies and preparations | |
| IL262176A (en) | Anti-tim-3 antibodies and preparations | |
| ZA201701244B (en) | Carrier-antibody compositions and methods of making and using the same | |
| IL250568A0 (en) | Anti-methanogenic preparations and their uses | |
| EP3206713A4 (en) | Interleukin-15 compositions and uses thereof | |
| IL247614B (en) | Methods and preparations for changing the immune response | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| GB201706352D0 (en) | Methods compositions and uses relating thereto | |
| EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
| SG11201605698XA (en) | Enolase 1 (eno1) compositions and uses thereof | |
| GB201706355D0 (en) | Methods compositions and uses relating thereto | |
| GB201706356D0 (en) | Methods compositions and uses relating thereto | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| GB201715785D0 (en) | Methods compositions and uses relating thereto | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| GB201715820D0 (en) | Compositions and methods | |
| GB201705626D0 (en) | Compositions and methods | |
| EP3322405A4 (en) | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF | |
| ZA201807665B (en) | Methods and compositions | |
| GB201614897D0 (en) | Compositions and uses thereof | |
| GB201602409D0 (en) | Compositions and uses thereof | |
| ZA201807782B (en) | Methods and compositions | |
| GB201602406D0 (en) | Compositions and uses thereof | |
| GB201602404D0 (en) | Compositions and uses thereof | |
| GB201602398D0 (en) | Compositions and uses thereof |